THE IMPORTANCE OF TUMOR NECROSIS FACTOR ALPHA IN THE PROGNOSIS OF BREAST CANSER

Authors

  • Dilbarhon Urmanbayeva PhD, docent at the Department of Oncology, Andijan state medical institute, Andiijan, Uzbekistan Author
  • Uktamxon Adhamjonova 1 st year master degree students in oncology, Andijan State Medical Institute Author
  • Gulnozakhon Abdivokhobova 1 st year master degree students in oncology ,Andijan State Medical Institute Author
  • Shoxista Erkinova 1 st year master degree students in oncology ,Andijan State Medical Institute Author

Keywords:

TNF-α, breast cancer, prognosis, cytokines, tumor microenvironment

Abstract

Tumor necrosis factor alpha (TNF-α) is a multifunctional cytokine with a dual role in cancer biology, exhibiting both tumor-promoting and tumor-suppressive effects. This study provides a comprehensive analysis of TNF-α in breast cancer prognosis, integrating molecular, clinical, and translational perspectives. Elevated TNF-α levels are strongly associated with tumor progression, metastasis, and reduced survival rates. Mechanistically, TNF-α activates key oncogenic pathways, including NF-κB, MAPK, and PI3K/Akt. However, under controlled conditions, TNF-α may induce apoptosis in tumor cells. The findings highlight TNF-α as a promising prognostic biomarker and a potential therapeutic target in precision oncology

References

1. Aggarwal, B. B. (2003). Signalling pathways of the TNF superfamily: A double-edged sword. Nature Reviews Immunology, 3(9), 745–756. https://doi.org/10.1038/nri1184

2. Balkwill, F. (2009). Tumour necrosis factor and cancer. Nature Reviews Cancer, 9(5), 361–371. https://doi.org/10.1038/nrc2628

3. Ben-Baruch, A. (2006). Inflammation-associated immune suppression in cancer: The roles played by cytokines, chemokines and additional mediators. Seminars in Cancer Biology, 16(1), 38–52.

4. Chen, X., & Oppenheim, J. J. (2011). TNF-α: An activator of cancer progression? Cancer Immunology Research, 3(4), 345–349.

5. Gupta, S. C., Sundaram, C., Reuter, S., & Aggarwal, B. B. (2010). Inhibiting NF-κB activation by small molecules as a therapeutic strategy. Biochimica et Biophysica Acta, 1799(10–12), 775–787.

6. Karin, M. (2006). Nuclear factor-κB in cancer development and progression. Nature, 441(7092), 431–436. https://doi.org/10.1038/nature04870

7. Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008). Cancer-related inflammation. Nature, 454(7203), 436–444.

8. Mercogliano, M. F., Bruni, S., Mauro, F., Elizalde, P. V., & Schillaci, R. (2020). Tumor necrosis factor alpha blockade: An emerging therapeutic strategy for breast cancer. Breast Cancer Research, 22(1), 1–12.

9. Szlosarek, P. W., & Balkwill, F. R. (2003). Tumour necrosis factor alpha: A potential target for the therapy of solid tumours. The Lancet Oncology, 4(9), 565–573.

10. Waters, J. P., Pober, J. S., & Bradley, J. R. (2013). Tumour necrosis factor and cancer. Journal of Pathology, 230(2), 241–248. https://doi.org/10.1002/path.4188

Downloads

Published

2026-05-12